博雅生物:公司事件点评报告:血制品保持稳健增长,内生外延助力浆站拓展
China Resources Boya Bio-pharmaceutical (300294) 华鑫证券·2024-10-30 00:41
证 券 2024 年 10 月 29 日 研 报 告 公 司 研 究 究 | --- | --- | --- | |---------------------------------------------------------------------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...